Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024)
Influenza and Other Respiratory Viruses · 2025
DOI: 10.1111/irv.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Danilo Franco und 24 weiteren Autor:innen. Beteiligte Einrichtung: Modular Specialized Laboratory, Department of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Pana…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Antibodies, Monoclonal, Antibodies, Neutralizing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría Nacional de Ciencia, Tecnología e Innovación, Instituto de Salud Carlos III, COVIDSEQ-UNESPA.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalization in infants and children. Whole genome sequencing (WGS) plays a critical role in understanding the evolution and epidemiology of RSV. Limited studies have been conducted in Central America and the Caribbean, and none have specifically focused on lineages involved in recent outbreaks. Furthermore, no assays currently exist to evaluate the sensitivity of the RSV fusion protein to monoclonal antibodies.
Methods
In Panama, an epidemiological surveillance system tracks RSV activity through the collection of nasopharyngeal samples from patients with acute respiratory infections. Between January 2018 and July 2024, 303 RSV‐positive samples were analyzed by RT‐qPCR. RSV‐B was the dominant subgroup in 2018, but following years had alternating dominance between RSV‐A and RSV‐B. Of the 303 samples, 115 underwent WGS. Additionally, neutralization assays were done using different Anti‐F Monoclonal Antibodies.
Results
In RSV‐A, 11 lineages were identified, with 3 to 5 cocirculating during each annual outbreak, and a shift in predominance from A.D .1 (2019) to A.D .5.2 (2023–2024). In RSV‐B, two lineages circulated: B.D.4.1.1 (2018–2020) and its descendant B.D.E.1, which predominated from 2021 onward. Several monoclonal antibodies, including nirsevimab's precursor MEDI8897*, effectively neutralized the RSV strains in neutralization assays.
Conclusions
Although Panama has not yet implemented a preventive therapy for RSV, this step could modify outbreak dynamics. The findings from this study provide a baseline reference prior to the implementation of preventive therapies against RSV in Panama and the region, facilitating the assessment of potential changes in the evolutionary dynamics of the virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Modular Specialized Laboratory, Department of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
- Programa de Desarrollo en Ciencias Básicas (PEDECIBA), Universidad de La República, Montevideo, Uruguay.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Department of Genomic and Proteomic, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
- National Research System (SNI), National Secretary of Research, Technology and Innovation (SENACYT), Panama City, Panama.
- Departamento de Microbiología, Facultad de Medicina, Escuela de Medicina, Universidad de Panamá, Panama City, Panama.
ORCID-Profile: Danilo Franco, Ambar Moreno, Zeuz Capitan-Barrios, Suman R Das, Leyda Ábrego
Förderung
- Secretaría Nacional de Ciencia, Tecnología e Innovación
- Instituto de Salud Carlos III
- COVIDSEQ-UNESPA
- EU4Health Programme (EU4H)
Zitieren
APA
Franco, D., Goya, S., Martínez, A., Mas, V., Moreno, B., Valdespino, E., Gaitán, M., Sáenz, L., González, C., Moreno, A., Capitan-Barrios, Z., Carrera, J. P., López-Vergès, S., Pascale, J. M., Moltó, Y., Moreno, L., Rizo, B., Urriola, E., Delgado, T., …, & Ábrego, L. (2025). Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024). Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70173
Vancouver
Franco D, Goya S, Martínez A, Mas V, Moreno B, Valdespino E, et al. Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024). Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70173
BibTeX
@article{Franco2025,
author = {Franco, Danilo and Goya, Stephanie and Martínez, Alexander and Mas, Vicente and Moreno, Brechla and Valdespino, Elimelec and Gaitán, Melissa and Sáenz, Lisseth and González, Claudia and Moreno, Ambar and Capitan-Barrios, Zeuz and Carrera, Jean Paul and López-Vergès, Sandra and Pascale, Juan Miguel and Moltó, Yadira and Moreno, Lourdes and Rizo, Belmaris and Urriola, Enrique and Delgado, Teresa and Iglesias-Caballero, María and Casas, Inmaculada and Das, Suman R and Arbiza, Juan and Delfraro, Adriana and Ábrego, Leyda},
title = {Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024)},
journal = {Influenza and Other Respiratory Viruses},
year = {2025},
doi = {10.1111/irv.70173}
}
EUVIMED